- Author: Juan Pablo Castanedo-Cazares, MD, MSc; Chief Editor: Dirk M Elston, MD more...
Actinic prurigo (AP) is a chronic, pruritic skin disease caused by an abnormal reaction to sunlight. In 1954, Escalona first described it in Mexico. Lesions appear hours or days following sun exposure, contrary to what happens in solar urticaria, in which skin lesions appear minutes after UV exposure. It is commonly associated with cheilitis and conjunctivitis.[2, 3] See the images below.
No systemic or local photosensitizer is known in patients with actinic prurigo, and a hypersensitivity implicating immunoglobulin E (IgE) has not been demonstrated.
Actinic prurigo has many features of a type IV hypersensitivity reaction. Skin lesions associated with actinic prurigo are infiltrated with T lymphocytes, mostly CD4+, and some of the T-cells express activation markers. Actinic prurigo falls in the category of autoimmune diseases because lymphocytes from patients have been proven to be stimulated in a thymidine incorporation assay when confronted with their own UV-irradiated keratinocytes or UV-irradiated epidermal homogenates.
At this point, the antigen that provokes the inflammatory reaction is not clear, but an epidermal protein is believed to be transformed by UV exposure. In the series by Santos-Martinez et al, the presence of transforming growth factor-beta interleukin 13, and interleukin 10 was demonstrated in a non–type-TH1, non–type-TH2 pattern, similar to what has been shown in lesions of psoriasis and in the synovial fluid of rheumatoid arthritis.
Another potentially important finding in the pathogenesis of actinic prurigo may be the fact that Langerhans cells in persons with actinic prurigo show resistance to UV exposure when compared with those in healthy individuals. This same finding has been shown in patients with a similar disease, polymorphous light eruption (PLE). Because these cells are resistant to their demise after UV exposure, they might handle and deliver UV-modified cutaneous antigens to T cells in larger amounts or in a more persistent way; this process could cause or augment the inflammatory phenomenon that is observed in the skin of patients with actinic prurigo. The apoptotic mechanism in these cells may be somewhat altered, facilitating their survival.
On the other hand, the polyclonal cellular immune response found in biopsy samples from Mexican patients through Southern blot analysis may involve an imbalance linked to a specific hyperimmunity, in which the proportion of autoimmune cells is increased and the proportion of other cells is decreased.
Although different series are searching for a specific HLA, studies have shown associations with B40 and CW3 alleles in some populations, especially Amerindians.[9, 10] For instance, in the Chimila Indians from Colombia, a high frequency of HLA-Cw4 was found. However, in Cree Indians from Saskatchewan, Canada, the most common antigens were HLA-A24 and HLA-Cw4.
Other studies have shown a strong association with HLA-DR4. The more precise finding appears to be in the Mexican series, in which HLA-DR4 DRB1*0407 is found in more than 90% of patients with actinic prurigo. Another series also found HLA-DR4 DRB1*0407 in Colombian patients. Related alleles such as DRB*0407 have been found in British populations, and DRB1*14 has been found in the Inuit Indians of Canada.
Additional to the role of HLA-DR4 DRB1*0407 in the genetic susceptibility to develop actinic prurigo, HLA-DRB1*1406 could also be involved, and HLA-DRB1*0802 may possibly have a protective role. The existence of an HLA-B39-DRB1*0407 haplotype suggests a susceptibility region within the sixth human chromosome, at least among Amerindians affected by actinic prurigo.
English patients with PLE have not shown an association with any HLA, which suggests that HLA-DR4 (DRB1*0407) could be used as a marker to distinguish PLE from actinic prurigo. Therefore, the association with HLA in actinic prurigo but not in PLE suggests that actinic prurigo represents an immunologically mediated disease with strong genetic determinants for its expression.[11, 13]
Actinic prurigo occurs in persons of all skin types, but its prevalence in the general population is unknown. It probably represents less than 5% of referrals to photodermatologic clinics. Actinic prurigo is well known in the United States among Native Americans.[10, 11, 18, 19]
In Mexico, actinic prurigo represents 1.34% of consultations with pediatric dermatologists and 4% of consultations with general dermatologists. Actinic prurigo is common in Mexico, Central America, and South America, and it is well known in Canada among Native Americans.[10, 11, 19] Actinic prurigo rarely occurs in Europe and Asia, where PLE (a disease with pathogenetic features similar to actinic prurigo) is more regularly seen. Isolated cases have been reported in France, Germany, Japan, Singapore, Thailand, and Australia. However, the prevalence rate of actinic prurigo in photodermatology clinics around the world varies from 0-5%.
Actinic prurigo frequently affects admixture populations (eg, mestizos) of Latin America and American Indians with skin phototypes IV or V.
In children and adolescents, no differences in prevalence exist between the sexes. However, in adults, women are more frequently affected than men, with a female-to-male ratio of 2:1.[1, 18]
Actinic prurigo can occur at any age; however, one third of patients are children. The impact on quality of life in this population is serious. By means of the children's dermatology life quality index (CDLQI), children with actinic prurigo show high scores and closer to those obtained in children with xeroderma pigmentosum.
Cazarin-Barrientos J, Roman D, Messina M. Talidomida en ninos con prurigo solar refractario. Actas Dermatol Dermatopatol. 2002. 1:11-5.
Herrera-Geopfert R, Magana M. Follicular cheilitis. A distinctive histopathologic finding in actinic prurigo. Am J Dermatopathol. 1995 Aug. 17(4):357-61. [Medline].
Magana M, Mendez Y, Rodriguez A, Mascott M. The conjunctivitis of solar (actinic) prurigo. Pediatr Dermatol. 2000 Nov-Dec. 17(6):432-5. [Medline].
Moncada B, Gonzalez-Amaro R, Baranda ML, Loredo C, Urbina R. Immunopathology of polymorphous light eruption. T lymphocytes in blood and skin. J Am Acad Dermatol. Jun 1984. 10(6):970-3. [Medline].
Gonzalez-Amaro R, Baranda L, Salazar-Gonzalez JF, Abud-Mendoza C, Moncada B. Immune sensitization against epidermal antigens in polymorphous light eruption. J Am Acad Dermatol. Jan 1991. 24(1):70-3. [Medline].
Santos-Martinez L, Llorente L, Baranda L, Richaud-Patin Y, Torres-Alvarez B, Moncada B, et al. Profile of cytokine mRNA expression in spontaneous and UV-induced skin lesions from actinic prurigo patients. Exp Dermatol. Apr 1997. 6(2):91-7. [Medline].
Torres-Alvarez B, Baranda L, Fuentes C, Delgado C, Santos-Martinez L, Portales-Perez D, et al. An immunohistochemical study of UV-induced skin lesions in actinic prurigo. Resistance of langerhans cells to UV light. Eur J Dermatol. Feb 1998. 8(1):24-8. [Medline].
Gonzalez-Rodriguez G, Ocadiz-Delgado R. [T and B clonal populations in actinic prurigo, a photodermatosis]. Gac Med Mex. 2001 Jan-Feb. 137(1):15-20. [Medline].
Wiseman MC, Orr PH, Macdonald SM, Schroeder ML, Toole JW. Actinic prurigo: clinical features and HLA associations in a Canadian Inuit population. J Am Acad Dermatol. 2001 Jun. 44(6):952-6. [Medline].
Schnell AH, Elston RC, Hull PR, Lane PR. Major gene segregation of actinic prurigo among North American Indians in Saskatchewan. Am J Med Genet. 2000 May 29. 92(3):212-9. [Medline].
Bernal JE, Duran de Rueda MM, Ordonez CP, Duran C, de Brigard D. Actinic prurigo among the Chimila Indians in Colombia: HLA studies. J Am Acad Dermatol. 1990 Jun. 22(6 Pt 1):1049-51. [Medline].
Sheridan DP, Lane PR, Irvine J, Martel MJ, Hogan DJ. HLA typing in actinic prurigo. J Am Acad Dermatol. 1990 Jun. 22(6 Pt 1):1019-23. [Medline].
Hojyo-Tomoka T, Granados J, Vargas-Alarcon G, Yamamoto-Furusho JK, Vega-Memije E, Cortes-Franco R, et al. Further evidence of the role of HLA-DR4 in the genetic susceptibility to actinic prurigo. J Am Acad Dermatol. Jun 1997. 36(6 Pt 1):935-7. [Medline].
Surez A, Valbuena MC, Rey M, de Porras Quintana L. Association of HLA subtype DRB10407 in Colombian patients with actinic prurigo. Photodermatol Photoimmunol Photomed. Apr 2006. 22(2):55-8. [Medline].
Menage H duP , Vaughan RW, Baker CS, Page G, Proby CM, Breathnach SM, et al. HLA-DR4 may determine expression of actinic prurigo in British patients. J Invest Dermatol. Feb 1996. 106(2):362-7. [Medline].
Zuloaga-Salcedo S, Castillo-Vazquez M, Vega-Memije E, Arellano-Campos O, Rodriguez-Perez JM, Perez-Hernandez N, et al. Class I and class II major histocompatibility complex genes in Mexican patients with actinic prurigo. Br J Dermatol. 2007. 156(5):1074-75. [Medline].
Grabczynska SA, McGregor JM, Kondeatis E, Vaughan RW, Hawk JL. Actinic prurigo and polymorphic light eruption: common pathogenesis and the importance of HLA-DR4/DRB1*0407. Br J Dermatol. 1999 Feb. 140(2):232-6. [Medline].
Hojyo-Tomoka T, Vega-Memije E, Granados J, Flores O, Cortes-Franco R, Teixeira F, et al. Actinic prurigo: an update. Int J Dermatol. Jun 1995. 34(6):380-4. [Medline].
Hojyo-Tomoka MT, Vega-Memije ME, Cortes-Franco R, Dominguez-Soto L. Diagnosis and treatment of actinic prurigo. Dermatol Ther. 2003. 16(1):40-4. [Medline].
Batard ML, Bonnevalle A, Segard M, Danze PM, Thomas P. Caucasian actinic prurigo: 8 cases observed in France. Br J Dermatol. 2001 Jan. 144(1):194-6. [Medline].
Worret WI, Vocks E, Frias G, Burgdorf WH, Lane P. [Actinic prurigo. An assessment of current status]. Hautarzt. 2000 Jul. 51(7):474-8. [Medline].
Kuno Y, Sato K, Hasegawa K, Tsuji T. A case of actinic prurigo showing hypersensitivity of skin fibroblasts to ultraviolet A (UVA). Photodermatol Photoimmunol Photomed. 2000. 16:38-41. [Medline].
Wong SN, Khoo LS. Analysis of photodermatoses seen in a predominantly Asian population at a photodermatology clinic in Singapore. Photodermatol Photoimmunol Photomed. 2005. 21:40-44. [Medline].
Akaraphanth R, Gritiyarangsan P. A case of actinic prurigo in Thailand. J Dermatol. 2000 Jan. 27(1):20-3. [Medline].
Crouch R, Foley P, Baker C. Actinic prurigo: a retrospective analysis of 21 cases referred to an Australian photobiology clinic. Australas J Dermatol. 2002 May. 43(2):128-32. [Medline].
Rizwan M, Haylett AK, Richards HL, Ling TC, Rhodes LE. Impact of photosensitivity disorders on the life quality of children. Photodermatol Photoimmunol Photomed. 2012 Dec. 28(6):290-2. [Medline].
Magana M. Actinic or solar prurigo. J Am Acad Dermatol. 1997 Mar. 36(3 Pt 1):504-5. [Medline].
Estrada-G I, Garibay-Escobar A, Nunez-Vazquez A, Hojyo-Tomoka T, Vega-Memije E, Cortes-Franco R, et al. Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo. Int J Dermatol. 2004. 43:893-897. [Medline].
Londono F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol. 1973 Sep-Oct. 12(5):326-8. [Medline].
Moncada B, Baranda ML, Gonzalez-Amaro R, Urbina R, Loredo CE. Thalidomide--effect on T cell subsets as a possible mechanism of action. Int J Lepr Other Mycobact Dis. Jun 1985. 53(2):201-5. [Medline].
Torres-Alvarez B, Castanedo-Cazares JP, Moncada B. Pentoxifylline in the treatment of actinic prurigo. A preliminary report of 10 patients. Dermatology. 2004. 208(3):198-201. [Medline].
McCoombes JA, Hirst LW, Green WR. Use of topical cyclosporin for conjunctival manifestations of actinic prurigo. Am J Ophthalmol. 2000. 130(6):830-831. [Medline].
Jong CT, Finlay AY, Pearse AD, Kerr AC, Ferguson J, Benton EC, et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol. 2008. 159(1):192-97. [Medline].